JAZZ PHARMACEUTICAL (J7Z.SG)
JAZZ PHARMACEUTICAL (J7Z.SG) operates in Diversified Metals & Mining.
JAZZ PHARMACEUTICAL (J7Z.SG) (J7Z) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.096x
Based on the latest financial reports, JAZZ PHARMACEUTICAL (J7Z.SG) (J7Z) has a cash flow conversion efficiency ratio of 0.096x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€398.75 Million) by net assets (€4.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
JAZZ PHARMACEUTICAL (J7Z.SG) - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how JAZZ PHARMACEUTICAL (J7Z.SG)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
JAZZ PHARMACEUTICAL (J7Z.SG) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of JAZZ PHARMACEUTICAL (J7Z.SG) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forbidden Foods Ltd
AU:FFF
|
-0.112x |
|
Oscar Properties Holding AB
ST:OP
|
0.151x |
|
Lord Resources Ltd
AU:LRD
|
-0.317x |
|
Fibon Bhd
KLSE:0149
|
0.053x |
|
FED AGRIC MTG -C-
BE:A35
|
-0.030x |
|
Kancera AB (publ)
ST:KAN
|
-0.227x |
|
Universal Biosensors Inc
AU:UBI
|
-0.301x |
|
Asiabasemetals Inc
V:ABZ
|
-0.004x |
Annual Cash Flow Conversion Efficiency for JAZZ PHARMACEUTICAL (J7Z.SG) (2016–2023)
The table below shows the annual cash flow conversion efficiency of JAZZ PHARMACEUTICAL (J7Z.SG) from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €3.74 Billion | €1.09 Billion | 0.292x | -29.11% |
| 2022-12-31 | €3.09 Billion | €1.27 Billion | 0.412x | +109.95% |
| 2021-12-31 | €3.97 Billion | €778.51 Million | 0.196x | -20.13% |
| 2020-12-31 | €3.66 Billion | €899.65 Million | 0.246x | -1.50% |
| 2019-12-31 | €3.11 Billion | €776.40 Million | 0.250x | -13.86% |
| 2018-12-31 | €2.76 Billion | €798.90 Million | 0.290x | +13.41% |
| 2017-12-31 | €2.71 Billion | €693.09 Million | 0.255x | -18.79% |
| 2016-12-31 | €1.88 Billion | €590.54 Million | 0.315x | -- |